Karavani Gilad, Strich David, Edri Shalom, Gillis David
Hebrew University Hadassah School of Medicine (G.K.), Jerusalem 91120, Israel; Clalit Health Services (D.S.), Jerusalem 95146, Israel; Shaare Zedek Medical Center (D.S.), Jerusalem 91031, Israel; Health Information Center (S.E.), Clalit Health Services, Jerusalem 95146, Israel; and Hadassah-Hebrew University Medical Center (D.G.), Jerusalem 91120, Israel.
J Clin Endocrinol Metab. 2014 Aug;99(8):E1471-5. doi: 10.1210/jc.2014-1441. Epub 2014 May 30.
TSH has been shown in vitro to increase conversion of T4 to T3 and to preferentially increase thyroidal T3 secretion. Whether or not these effects are significant in vivo, other than in obesity, is unclear.
To test whether the incremental relationships between free T4 (FT4), free T3 (FT3), and TSH are compatible with TSH enhancement of a preferential increase in serum FT3.
A large database of pediatric and adolescent thyroid test results drawn in community clinics from children and adolescents without known thyroid disease was analyzed.
RESULTS of FT3, FT4, and TSH were studied anonymously. They were crossed with electronic charts to exclude a history of positive thyroid autoantibodies and use of thyroid hormone preparations, antithyroid medication, or drugs known to affect thyroid function. All samples from patients appearing more than once in the database were removed. After exclusions, 3276 samples remained. FT4, FT3, and the FT3/FT4 ratios were correlated with TSH for the entire group, and the same parameters were segregated by TSH quartile. RESULTS were stratified for body mass index and studied separately in a normal-weight subgroup.
Stepwise correlations of FT4, FT3, and FT3/FT4 ratios with TSH.
There was a significant positive linear correlation of TSH with FT3 and FT3/FT4 ratios (R = 0.12; P < .0001 in both), but not with FT4.
Within the near-euthyroid range, increasing TSH levels are associated with increasing FT3 levels, without an increase in FT4. This provides in vivo support for TSH enhancing preferentially T3 production and/or secretion.
体外实验表明,促甲状腺激素(TSH)可增加甲状腺素(T4)向三碘甲状腺原氨酸(T3)的转化,并优先增加甲状腺T3的分泌。除肥胖外,这些作用在体内是否显著尚不清楚。
检验游离T4(FT4)、游离T3(FT3)与TSH之间的增量关系是否与TSH促进血清FT3优先增加相符。
分析了社区诊所中无已知甲状腺疾病的儿童和青少年的大量儿科及青少年甲状腺检测结果数据库。
对FT3、FT4和TSH的结果进行匿名研究。将其与电子病历交叉核对,以排除甲状腺自身抗体阳性病史以及使用甲状腺激素制剂、抗甲状腺药物或已知影响甲状腺功能药物的情况。数据库中多次出现的患者的所有样本均被剔除。排除后,剩余3276个样本。对整个组的FT4、FT3及FT3/FT4比值与TSH进行相关性分析,并按TSH四分位数对相同参数进行分类。结果按体重指数分层,并在正常体重亚组中单独研究。
FT4、FT3及FT3/FT4比值与TSH的逐步相关性。
TSH与FT3及FT3/FT4比值呈显著正线性相关(两者R = 0.12;P <.0001),但与FT4无相关性。
在接近甲状腺功能正常范围内,TSH水平升高与FT3水平升高相关,而FT4不升高。这为TSH优先促进T3生成和/或分泌提供了体内证据。